Timing the Next Infusion Around a Vaccine That Might Not Take
A scheduling collision, not a clinical one: her seventh ocrelizumab infusion and a travel vaccine series land in the same month. Moving the infusion buys a better antibody response and costs a schedule that has not needed touching in three years. Whether that trade is worth making turns on which vaccines, against what.
S.O. spent two years arranging a six-week volunteer posting at a rural clinic overseas, applying twice before a placement came through. She is 41, a physician assistant, and the trip requires a vaccine series she has never needed. It falls in the same month as her seventh ocrelizumab infusion — a collision nobody noticed until the travel-clinic appointment landed on the calendar beside the infusion date. Her CD19 count, checked five months post-infusion, is undetectable, which is expected and, for the first time in three years, inconvenient.
Her MS has been silent for the five years since diagnosis and the three she has been on this drug. What has changed sits elsewhere in the chart: three sinus infections requiring antibiotics in fourteen months, and an IgG that has drifted from 720 to 580 mg/dL, under the lab's reference floor for the first time. B-cell depletion is doing precisely what it was prescribed to do, and the question is whether it is also depleting the compartment her vaccine needs intact before she is six weeks from the nearest infectious-disease service. Response magnitude in anti-CD20-treated patients tracks distance from the last infusion rather than switching on at a threshold, and the extended-dosing cohorts Zanghì and Rolfes each followed, built around individualized B-cell repletion rather than a fixed six-month calendar, did not show more breakthrough disease for the delay. Her infusion date sits close enough to departure that widening the gap is genuinely available — at the cost of moving a schedule that, measured against her MS alone, has never needed moving.
Six weeks before departure, reviewing the calendar
I'd extend her interval, giving the vaccine series once her B cells have had a chance to partially replete rather than right at nadir. Zanghì and colleagues, and Rolfes and colleagues separately, followed ocrelizumab cohorts dosed on individualized B-cell repletion rather than a fixed six-month calendar and did not see meaningfully more breakthrough activity; and across the mRNA-vaccine literature in anti-CD20-treated patients, antibody response tracks with distance from the last infusion rather than switching on at a threshold.
I also can't ignore that she's already had three sinus infections in fourteen months with her IgG trending down — that's an independent reason to want her B-cell compartment to recover some, separate from the vaccine question entirely.
Her disease has been completely silent for three years on the current schedule. I'd hold to standard dosing and give the vaccine on the calendar as planned — disrupting a regimen that's working, for a single vaccination event, is a real cost if it doesn't hold, not a hypothetical one.
I take the infection history seriously, but three sinus infections over fourteen months in a patient on chronic B-cell depletion isn't yet the same as a pattern that's forcing our hand on the dosing schedule itself — I'd want to see that trend continue before treating it as decisive here.
I don't think this resolves as a general 'vaccine response is blunted' question — it depends on what she's actually being vaccinated against and what a partial response protects her from. If the exposures at her posting are the kind where even a reduced antibody titer meaningfully lowers risk, that changes the calculation from either of your general positions.
You're both right about your own evidence, and neither of you is wrong that this is a real tradeoff. But 'extend the interval' and 'hold the schedule' are both premature answers until we've actually looked at which specific vaccines this posting requires and how much a blunted-but-present response is worth against each one.
Agreed: this single infusion is shifted by five weeks to open a wider gap before the travel vaccine series, with the schedule returning to standard six-month dosing immediately afterward — a one-time exception, not a new baseline interval. IgG and CD19 rechecked before the extended dose is given, so the group has current numbers rather than reasoning from labs drawn months earlier.
Not agreed: whether the recent infection pattern is itself grounds for a more durable change to her dosing interval, separate from the vaccine question entirely. That question was named explicitly rather than folded into today's decision — the group agreed to revisit it directly once she returns from her posting, with fresh infection and IgG data rather than deciding it now on an incomplete trend.